Fabio Arturo Iannotti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9326830/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	<i>N</i> â€Acylethanolamine acid amidase (NAAA) is dysregulated in colorectal cancer patients and its inhibition reduces experimental cancer growth. British Journal of Pharmacology, 2022, 179, 1679-1694.	2.7	6
2	Early Blockade of CB1 Receptors Ameliorates Schizophrenia-like Alterations in the Neurodevelopmental MAM Model of Schizophrenia. Biomolecules, 2022, 12, 108.	1.8	9
3	Three of a Kind: Control of the Expression of Liver-Expressed Antimicrobial Peptide 2 (LEAP2) by the Endocannabinoidome and the Gut Microbiome. Molecules, 2022, 27, 1.	1.7	38
4	Crosstalk between the transcriptional regulation of dopamine D2 and cannabinoid CB1 receptors in schizophrenia: Analyses in patients and in perinatal l"9-tetrahydrocannabinol-exposed rats. Pharmacological Research, 2021, 164, 105357.	3.1	43
5	Beneficial Effects of Akkermansia muciniphila Are Not Associated with Major Changes in the Circulating Endocannabinoidome but Linked to Higher Mono-Palmitoyl-Clycerol Levels as New PPARα Agonists. Cells, 2021, 10, 185.	1.8	43
6	The gut microbiome, endocannabinoids and metabolic disorders. Journal of Endocrinology, 2021, 248, R83-R97.	1.2	46
7	2-Pentadecyl-2-oxazoline ameliorates memory impairment and depression-like behaviour in neuropathic mice: possible role of adrenergic alpha2- and H3 histamine autoreceptors. Molecular Brain, 2021, 14, 28.	1.3	13
8	N-palmitoyl-D-glucosamine, A Natural Monosaccharide-Based Glycolipid, Inhibits TLR4 and Prevents LPS-Induced Inflammation and Neuropathic Pain in Mice. International Journal of Molecular Sciences, 2021, 22, 1491.	1.8	19
9	The Endocannabinoid System and PPARs: Focus on Their Signalling Crosstalk, Action and Transcriptional Regulation. Cells, 2021, 10, 586.	1.8	55
10	The (Poly)Pharmacology of Cannabidiol in Neurological and Neuropsychiatric Disorders: Molecular Mechanisms and Targets. International Journal of Molecular Sciences, 2021, 22, 4876.	1.8	37
11	Identification and Characterization of Cannabidiol as an OX1R Antagonist by Computational and In Vitro Functional Validation. Biomolecules, 2021, 11, 1134.	1.8	8
12	Duchenne's muscular dystrophy involves a defective transsulfuration pathway activity. Redox Biology, 2021, 45, 102040.	3.9	15
13	Maternal omega-3 intake differentially affects the endocannabinoid system in the progeny`s neocortex and hippocampus: Impact on synaptic markers. Journal of Nutritional Biochemistry, 2021, 96, 108782.	1.9	5
14	Efficacy of combined therapy with fish oil and phytocannabinoids in murine intestinal inflammation. Phytotherapy Research, 2021, 35, 517-529.	2.8	21
15	Orexin-A and endocannabinoids are involved in obesity-associated alteration of hippocampal neurogenesis, plasticity, and episodic memory in mice. Nature Communications, 2021, 12, 6137.	5.8	22
16	Assessment of the Effects of Dietary Vitamin D Levels on Olanzapine-Induced Metabolic Side Effects: Focus on the Endocannabinoidome-Gut Microbiome Axis. International Journal of Molecular Sciences, 2021, 22, 12361.	1.8	4
17	Oleoyl alanine (HU595): a stable monomethylated oleoyl glycine interferes with acute naloxone precipitated morphine withdrawal in male rats. Psychopharmacology, 2020, 237, 2753-2765.	1.5	11
18	Treatment With 2-Pentadecyl-2-Oxazoline Restores Mild Traumatic Brain Injury-Induced Sensorial and Neuropsychiatric Dysfunctions. Frontiers in Pharmacology, 2020, 11, 91.	1.6	15

Fabio Arturo Iannotti

#	Article	IF	CITATIONS
19	Identification and Characterization of Cannabimovone, a Cannabinoid from Cannabis sativa, as a Novel PPARÎ ³ Agonist via a Combined Computational and Functional Study. Molecules, 2020, 25, 1119.	1.7	20
20	Phytocannabinoids promote viability and functional adipogenesis of bone marrow-derived mesenchymal stem cells through different molecular targets. Biochemical Pharmacology, 2020, 175, 113859.	2.0	17
21	Protective Effects of <i>N</i> -Oleoylglycine in a Mouse Model of Mild Traumatic Brain Injury. ACS Chemical Neuroscience, 2020, 11, 1117-1128.	1.7	15
22	Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment. Biochemical Pharmacology, 2020, 177, 114004.	2.0	36
23	Effects of nonâ€euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice. British Journal of Pharmacology, 2019, 176, 1568-1584.	2.7	51
24	Activation of Kv7 Potassium Channels Inhibits Intracellular Ca2+ Increases Triggered By TRPV1-Mediated Pain-Inducing Stimuli in F11 Immortalized Sensory Neurons. International Journal of Molecular Sciences, 2019, 20, 4322.	1.8	8
25	The non-euphoric phytocannabinoid cannabidivarin counteracts intestinal inflammation in mice and cytokine expression in biopsies from UC pediatric patients. Pharmacological Research, 2019, 149, 104464.	3.1	55
26	In Silico Identification and Experimental Validation of (â^')-Muqubilin A, a Marine Norterpene Peroxide, as PPARα/γ-RXRα Agonist and RARα Positive Allosteric Modulator. Marine Drugs, 2019, 17, 110.	2.2	11
27	Pharmacological Actions and Potential Therapeutic Use of Cannabinoids in Duchenne's Muscular Dystrophy. , 2019, , .		0
28	Palmitoylethanolamide counteracts substance P-induced mast cell activation in vitro by stimulating diacylglycerol lipase activity. Journal of Neuroinflammation, 2019, 16, 274.	3.1	39
29	Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia. Neuropharmacology, 2019, 146, 212-221.	2.0	59
30	Identification and characterization of phytocannabinoids as novel dual PPARα/γ agonists by a computational and in vitro experimental approach. Biochimica Et Biophysica Acta - General Subjects, 2019, 1863, 586-597.	1.1	55
31	Nociceptor plasticity: A closer look. Journal of Cellular Physiology, 2018, 233, 2824-2838.	2.0	42
32	Antibiotic-induced microbiota perturbation causes gut endocannabinoidome changes, hippocampal neuroglial reorganization and depression in mice. Brain, Behavior, and Immunity, 2018, 67, 230-245.	2.0	246
33	Genetic and pharmacological regulation of the endocannabinoid CB1 receptor in Duchenne muscular dystrophy. Nature Communications, 2018, 9, 3950.	5.8	43
34	Experimental ischemia/reperfusion model impairs endocannabinoid signaling and Na+/K+ ATPase expression and activity in kidney proximal tubule cells. Biochemical Pharmacology, 2018, 154, 482-491.	2.0	15
35	Role of the endocannabinoid system in the control of mouse myometrium contractility during the menstrual cycle. Biochemical Pharmacology, 2017, 124, 83-93.	2.0	10
36	Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor. Scientific Reports, 2017, 7, 375.	1.6	103

#	Article	IF	CITATIONS
37	Exercise training and high-fat diet elicit endocannabinoid system modifications in the rat hypothalamus and hippocampus. Journal of Physiology and Biochemistry, 2016, 73, 335-347.	1.3	16
38	Early Low-Fat Diet Enriched With Linolenic Acid Reduces Liver Endocannabinoid Tone and Improves Late Glycemic Control After a High-Fat Diet Challenge in Mice. Diabetes, 2016, 65, 1824-1837.	0.3	20
39	Effects of chronic exercise on the endocannabinoid system in Wistar rats with high-fat diet-induced obesity. Journal of Physiology and Biochemistry, 2016, 72, 183-199.	1.3	20
40	Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders. Progress in Lipid Research, 2016, 62, 107-128.	5.3	276
41	Human lung-resident macrophages express CB1 and CB2 receptors whose activation inhibits the release of angiogenic and lymphangiogenic factors. Journal of Leukocyte Biology, 2016, 99, 531-540.	1.5	98
42	The endocannabinoid system in renal cells: regulation of <scp><scp>Na</scp></scp> ⁺ transport by <scp>CB</scp> ₁ receptors through distinct cell signalling pathways. British Journal of Pharmacology, 2015, 172, 4615-4625.	2.7	35
43	Neuroendocrine Transdifferentiation in Human Prostate Cancer Cells: An Integrated Approach. Cancer Research, 2015, 75, 2975-2986.	0.4	39
44	Nonpsychotropic Plant Cannabinoids, Cannabidivarin (CBDV) and Cannabidiol (CBD), Activate and Desensitize Transient Receptor Potential Vanilloid 1 (TRPV1) Channels in Vitro: Potential for the Treatment of Neuronal Hyperexcitability. ACS Chemical Neuroscience, 2014, 5, 1131-1141.	1.7	301
45	The endocannabinoid 2-AG controls skeletal muscle cell differentiation via CB1 receptor-dependent inhibition of K _v 7 channels. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E2472-81.	3.3	75
46	The dual blocker of FAAH/TRPV1 N-arachidonoylserotonin reverses the behavioral despair induced by stress in rats and modulates the HPA-axis. Pharmacological Research, 2014, 87, 151-159.	3.1	66
47	Rimonabant Precipitates Anxiety in Rats Withdrawn from Palatable Food: Role of the Central Amygdala. Neuropsychopharmacology, 2013, 38, 2498-2507.	2.8	54
48	Analysis of the "endocannabinoidome―in peripheral tissues of obese Zucker rats. Prostaglandins Leukotrienes and Essential Fatty Acids, 2013, 89, 127-135.	1.0	41
49	The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG. Cell Death and Disease, 2013, 4, e862-e862.	2.7	69
50	Specification of skeletal muscle differentiation by repressor element-1 silencing transcription factor (REST)-regulated K _v 7.4 potassium channels. Molecular Biology of the Cell, 2013, 24, 274-284.	0.9	42
51	The Voltage-Sensing Domain of Kv7.2 Channels as a Molecular Target for Epilepsy-Causing Mutations and Anticonvulsants. Frontiers in Pharmacology, 2011, 2, 2.	1.6	24
52	Preâ€synaptic BK channels selectively control glutamate versus GABA release from cortical and hippocampal nerve terminals. Journal of Neurochemistry, 2010, 115, 411-422.	2.1	43
53	Neuronal potassium channel openers in the management of epilepsy: role and potential of retigabine. Clinical Pharmacology: Advances and Applications, 2010, 2, 225.	0.8	23
54	Expression, Localization, and Pharmacological Role of K _v 7 Potassium Channels in Skeletal Muscle Proliferation, Differentiation, and Survival after Myotoxic Insults. Journal of Pharmacology and Experimental Therapeutics, 2010, 332, 811-820.	1.3	65

#	Article	IF	CITATIONS
55	Activation of preâ€synaptic Mâ€type K ⁺ channels inhibits [³ H] <scp>d</scp> â€aspartate release by reducing Ca ²⁺ entry through P/Qâ€type voltageâ€gated Ca ²⁺ channels. Journal of Neurochemistry, 2009, 109, 168-181.	2.1	25
56	Involvement of KCNQ2 subunits in [3H]dopamine release triggered by depolarization and pre-synaptic muscarinic receptor activation from rat striatal synaptosomes. Journal of Neurochemistry, 2007, 102, 179-193.	2.1	51